ESR1 and breast carcinoma: This result might be understandable considering that ER− tumors have higher pCR rates than ER+ tumors among patients with HER2+ breast cancers in clinical trials15 and that HER2+ tumors respond better to NAC (plus trastuzumab) than HER2− tumors.27